YGION Biomedical announces €15 Million Series A Financing to develop Individualized Cancer Immunotherapies
Summary
VIENNA, May 21, 2024 /PRNewswire/ -- YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A financing round of 15 million from an Austrian private trust. The proceeds will be used to further develop YGIONs unique YGNITETM technology platform and advance the lead program YG-01 into preclinical and clinical development.Founded in 2022, YGIONs high-profile team of experienced biotech veterans and entrepreneurs are focused on developing individualized "plug-and-play" cancer vaccines through a proprietary suite of technologies to identify, produce and target the delivery of relevant peptide neoepitopes resulting in safe, exceptionally potent, and precise targeted activation of the patients immune system. "We are on the cusp of a breakthrough in individualized cancer treatments" said Dr. Wolfgang Fischl, Chief Executive Officer of YGION. "Our YGNITETM platform gives us the unique ability to identify, select and synthesise relevant neoantigens, and combined with our CARGONAUTTM immune-modulating carrier induces a powerful cell-mediated tumor specific response that targets and eliminates malignant cells with unmatched safety. YGIONs YGNITE platform combines next generation sequencing, bioinformatics and the proprietary CARGONAUT vaccine platform to deliver neoepitope peptide vaccines tailored for each tumor and each patient.